Danapha Pharmaceutical JSC (HSTC:DAN) EBIT per Share: ₫ (TTM As of . 20)


HSTC:DAN Danapha Pharmaceutical JSC HSTC:DAN
30 GF Score
Price ₫30,300.00
! 1 Warning Sign
View Full Analysis

What is Danapha Pharmaceutical JSC EBIT per Share?

Danapha Pharmaceutical JSC HSTC:DAN 30 EBIT per Share is ₫ as of . 20. GuruFocus rates HSTC:DAN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 809 Drug Manufacturers companies, Danapha Pharmaceutical JSC ranks worse than 123609.27% on this metric.

Danapha Pharmaceutical JSC's EBIT per Share for the six months ended in . 20 was ₫0.00. Danapha Pharmaceutical JSC does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Danapha Pharmaceutical JSC's EBIT per Share or its related term are showing as below:

HSTC:DAN's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Danapha Pharmaceutical JSC's EBIT for the six months ended in . 20 was ₫0.00 Mil.

Danapha Pharmaceutical JSC  (HSTC:DAN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Danapha Pharmaceutical JSC EBIT per Share Related Terms

Danapha Pharmaceutical JSC EBIT per Share Historical Data

* Premium members only.

The historical data trend for Danapha Pharmaceutical JSC's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danapha Pharmaceutical JSC EBIT per Share Chart

Danapha Pharmaceutical JSC Annual Data
Trend
EBIT per Share

Danapha Pharmaceutical JSC Semi-Annual Data
EBIT per Share
HSTC:DAN
30GF Score
Danapha Pharmaceutical JSC HSTC:DAN
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Danapha Pharmaceutical JSC EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Danapha Pharmaceutical JSC's EBIT per Share for the fiscal year that ended in . 20 is calculated as

EBIT per Share(A: . 20 )
=EBIT/Shares Outstanding (Diluted Average)
=/0
=N/A

Danapha Pharmaceutical JSC's EBIT per Share for the quarter that ended in . 20 is calculated as

EBIT per Share(Q: . 20 )
=EBIT/Shares Outstanding (Diluted Average)
=/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of ₫ mean?
Danapha Pharmaceutical JSC (HSTC:DAN) has a EBIT per Share of ₫ as of . 20. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Danapha Pharmaceutical JSC and its competitors. According to the industry distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 809 companies in the Drug Manufacturers industry.
Is Danapha Pharmaceutical JSC's EBIT per Share too high?
Danapha Pharmaceutical JSC's current EBIT per Share is ₫. Based on the distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Danapha Pharmaceutical JSC has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Danapha Pharmaceutical JSC's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 809 companies for EBIT per Share. This places Danapha Pharmaceutical JSC in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Danapha Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danapha Pharmaceutical JSC's current EBIT per Share is ₫. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danapha Pharmaceutical JSC stock overvalued right now?
Danapha Pharmaceutical JSC (HSTC:DAN) has a current EBIT per Share of ₫. The current EBIT per Share is ₫. Danapha Pharmaceutical JSC's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Danapha Pharmaceutical JSC (HSTC:DAN), the current EBIT per Share is ₫ as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Danapha Pharmaceutical JSC Business Description

Address 253 Dung Si Thanh Khe, Da Nang, VNM
Danapha Pharmaceutical JSC is a manufacturer of herbal medicine and specific drugs such as central nervous system, neurotonics, anti-diabetics, cardiovascular drug, gastrointestinal and heaptic biliary system with forms such as tablets, capsules, injection, sirup, balm and medicated oil.
30GF Score

Get the complete analysis for HSTC:DAN

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫30,300.00
Price